tetano
Editor, Senior Moderator
Front Microbiol. 2019 Oct 30;10:2482. doi: 10.3389/fmicb.2019.02482. eCollection 2019. [h=1]Interleukin-37 Ameliorates Influenza Pneumonia by Attenuating Macrophage Cytokine Production in a MAPK-Dependent Manner.[/h]
Qi F[SUP]1,[/SUP][SUP]2[/SUP], Liu M[SUP]1,[/SUP][SUP]2[/SUP], Li F[SUP]1,[/SUP][SUP]2[/SUP], Lv Q[SUP]1,[/SUP][SUP]2[/SUP], Wang G[SUP]1,[/SUP][SUP]2[/SUP], Gong S[SUP]1,[/SUP][SUP]2[/SUP], Wang S[SUP]1,[/SUP][SUP]2[/SUP], Xu Y[SUP]1[/SUP], Bao L[SUP]1,[/SUP][SUP]2[/SUP], Qin C[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h] 1 NHC Key Laboratory of Human Disease Comparative Medicine, The Institute of Laboratory Animal Sciences, Peking Union Medical College Hospital (CAMS), Beijing, China. 2 Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious, The Institute of Laboratory Animal Sciences, Peking Union Medical College Hospital (CAMS), Beijing, China.
[h=3]Abstract[/h] Viral pneumonitis caused by influenza A (H1N1) virus leads to high levels of morbidity and mortality. Given the limited treatment options for severe influenza pneumonia, it is necessary to explore effective amelioration approaches. Interleukin-37 (IL-37) has been reported to inhibit excessive immune responses and protect against a variety of inflammatory diseases. In this study, by using BALB/c mice intranasally infected with A/California/07/2009 (H1N1), we found that IL-37 treatment increases the survival rate and body weight, and reduces the pulmonary index, impaired the lung injury and decreased production of pro-inflammatory cytokines in the BALF and lung tissue. Moreover, IL-37 administration enhanced not only the percentage of macrophages, but also the percentage of IL-18Rα[SUP]+[/SUP] macrophages, suggesting that enhancing the macrophages function may improve outcomes in a murine model of H1N1 infection. Indeed, macrophages depletion reduced the protective effect of IL-37 during H1N1 infection. Furthermore, IL-37 administration inhibited MAPK signaling in RAW264.7 cells infected with H1N1. This study demonstrates that IL-37 treatment can ameliorate influenza pneumonia by attenuating cytokine production, especially by macrophages. Thus, IL-37 might serve as a promising new target for the treatment of influenza A-induced pneumonia.
Copyright ? 2019 Qi, Liu, Li, Lv, Wang, Gong, Wang, Xu, Bao and Qin.
[h=4]KEYWORDS:[/h] A/California/07/2009 (H1N1); Interleukin-37; inflammation; macrophages; viral pneumonia
PMID: 31736917 PMCID: PMC6831648 DOI: 10.3389/fmicb.2019.02482
Free full text
Qi F[SUP]1,[/SUP][SUP]2[/SUP], Liu M[SUP]1,[/SUP][SUP]2[/SUP], Li F[SUP]1,[/SUP][SUP]2[/SUP], Lv Q[SUP]1,[/SUP][SUP]2[/SUP], Wang G[SUP]1,[/SUP][SUP]2[/SUP], Gong S[SUP]1,[/SUP][SUP]2[/SUP], Wang S[SUP]1,[/SUP][SUP]2[/SUP], Xu Y[SUP]1[/SUP], Bao L[SUP]1,[/SUP][SUP]2[/SUP], Qin C[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h] 1 NHC Key Laboratory of Human Disease Comparative Medicine, The Institute of Laboratory Animal Sciences, Peking Union Medical College Hospital (CAMS), Beijing, China. 2 Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious, The Institute of Laboratory Animal Sciences, Peking Union Medical College Hospital (CAMS), Beijing, China.
[h=3]Abstract[/h] Viral pneumonitis caused by influenza A (H1N1) virus leads to high levels of morbidity and mortality. Given the limited treatment options for severe influenza pneumonia, it is necessary to explore effective amelioration approaches. Interleukin-37 (IL-37) has been reported to inhibit excessive immune responses and protect against a variety of inflammatory diseases. In this study, by using BALB/c mice intranasally infected with A/California/07/2009 (H1N1), we found that IL-37 treatment increases the survival rate and body weight, and reduces the pulmonary index, impaired the lung injury and decreased production of pro-inflammatory cytokines in the BALF and lung tissue. Moreover, IL-37 administration enhanced not only the percentage of macrophages, but also the percentage of IL-18Rα[SUP]+[/SUP] macrophages, suggesting that enhancing the macrophages function may improve outcomes in a murine model of H1N1 infection. Indeed, macrophages depletion reduced the protective effect of IL-37 during H1N1 infection. Furthermore, IL-37 administration inhibited MAPK signaling in RAW264.7 cells infected with H1N1. This study demonstrates that IL-37 treatment can ameliorate influenza pneumonia by attenuating cytokine production, especially by macrophages. Thus, IL-37 might serve as a promising new target for the treatment of influenza A-induced pneumonia.
Copyright ? 2019 Qi, Liu, Li, Lv, Wang, Gong, Wang, Xu, Bao and Qin.
[h=4]KEYWORDS:[/h] A/California/07/2009 (H1N1); Interleukin-37; inflammation; macrophages; viral pneumonia
PMID: 31736917 PMCID: PMC6831648 DOI: 10.3389/fmicb.2019.02482
Free full text